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Non-small cell lung cancer (NSCLC) is the most common form of lung cancer. Genetic polymorphisms in tumour 
suppressor genes and genes encoding xenobiotic metabolising enzymes alter the activity of their corresponding enzymes 
and are important individual susceptibility factors for NSCLC. Because of the lack of information in literature, the aim 
of our study was to investigate the role of the tumour suppressor gene TP53 (Arg72Pro) and the xenobiotic metabolising 
CYP2E1*5B gene polymorphisms on the risk of NSCLC development. The study population consisted of 172 patients 
and 172 controls (156 men and 16 women in each group). Genetic polymorphisms were determined with real-time 
polymerase chain reaction (PCR) and PCR restriction fragment length polymorphism (PCR-RFLP). Multivariate analysis 
showed a significant association with NSCLC for the combination between the TP53 codon72 Arg/Pro and the Pro/Pro 
genotypes (OR 2.21, 95 % CI 1.39–3.51; p=0.001). We also analysed whether combinations of these gene variants with 
GSTM1, GSTT1, GSTP1 exon 5 (Ile105Val), and GSTP1 exon 6 (Ala114Val) gene polymorphisms were associated with 
the NSCLC risk. A significant increase in the risk was observed for the following combinations: TP53 codon72 variant 
with GSTM1 null (OR 2.22, 95 % CI 1.23-4.04; p=0.009), GSTT1 null (OR 2.98, 95 % CI 1.49-5.94; p=0.002), and GSTP1 
(Ala114Val) variant genotypes (OR 3.38, 95 % CI 1.54-7.41; p=0.002). Further studies with larger samples are needed 
to verify these findings.
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Lung cancer is the most common cancer type in the 
world, which affects men in particular. It is also the leading 
cause of death among cancers (1). Histologically, about 
80 % of lung cancers are non-small cell lung carcinomas 
(NSCLC). The inbuilt phase I and II biotransformation 
enzyme systems inactivate environmental carcinogens, 
especially those present in tobacco smoke, depending on 
the regulating polymorphisms. Epidemiological studies 
show that genetic differences and interactions among 
genetic variants might modify lung cancer susceptibility 
(2, 3). Therefore, it is important to identify individual 
genetic and acquired factors that modify lung cancer risk 
in order to develop preventive strategies based on this 
information. This is particularly true for identifying 
polymorphisms of tumour suppressor genes and xenobiotic 
metabolising enzyme genes. The TP53 tumour suppressor 
gene is an essential regulator of the cell-cycle arrest, DNA 
repair, and apoptosis (4). An important single nucleotide 
polymorphism detected in TP53 is Arg72Pro. This allele 
has been shown to decrease the activity of the corresponding 
protein, which is crucial for the apoptotic function of TP53 
(5, 6). Recent studies have reported the association between 
this polymorphism and lung cancer (7-11).
CYP2E1 is an important phase I biotransformation 
enzyme that transforms N-nitrosamines, vinyl chloride, and 
benzene in tobacco smoke into mutagenic and carcinogenic 
metabolites (12). In NSCLC patients it has been found to 
be overexpressed (13). However, its CYP2E1*5B allele has 
been shown to reduce enzyme activity and microsomal 
oxidation capacity (14, 15).
The complex pathways of (pro)carcinogen metabolism 
and the possible interactions between the genes encoding 
enzymes and TP53 protein clearly indicate the need for 
their combined assessment as predisposing factors for 
NSCLC development. However, current findings on the 
overall impact of TP53, CYP2E1, and GST polymorphisms 
on NSCLC are limited and controversial (16-18). The aim 
of this study was to learn more about these impacts by 
investigating: a) the association between NSCLC risk and 
TP53 (Arg72Pro) and CYP2E1*5B polymorphisms either 
alone or in combination and b) possible gene interactions 
as risk modifiers for NSCLC by combining TP53 
(Arg72Pro) and CYP2E1*5B polymorphisms with phase II 
enzyme coding gene polymorphisms GSTM1, GST1, 
GSTP1 (Ile105Val) (rs1695), and GSTP1 (Ala114Val) 
Correspondence to: Ahmet Oguz Ada, Department of Toxicology, Faculty 
of Pharmacy, University of Ankara, 06100 Tandoğan, Ankara, Turkey; 
E mail: ada@pharmacy.ankara.edu.tr
Ada AO, et al. Association between the TP53 and CYP2E1*5B gene polymorphisms and non-small cell lung cancer 
Arh Hig Rada Toksikol 2016;67:311-316
312Ada AO, et al. Association between the TP53 and CYP2E1*5B gene polymorphisms and non-small cell lung cancer Arh Hig Rada Toksikol 2016;67:311-316
(rs1138272) that we have previously genotyped in NSCLC 
patients (19).
PARTICIPANTS AND METHODS
This case-control study included 344 participants, 172 
of whom were histologically confirmed NSCLC patients 
and 172 were matching controls by gender and mean age 
(±3 years). All NSCLC patients were enrolled at the Ataturk 
Pulmonary Diseases and Thoracic Surgery Hospital from 
February 2002 to November 2005. Their clinical data were 
collected from medical records. The staging and histological 
sub-typing of the lung carcinomas followed the international 
staging system for lung cancer and World Health 
Organisation histological classification of lung tumours 
(20). All other lung cancer types were excluded from the 
study.
Each patient had an interview to answer a detailed 
questionnaire about sociodemographic and history of 
smoking information. Pack years were calculated by 
multiplying packs smoked per day with years as a smoker.
The control group was recruited at a local healthcare 
centre and consisted of volunteers who were informed about 
the study during their routine health check-ups. The 
exclusion criteria were history of malignancy, pregnancy, 
chronic diseases, and diagnosed cancer of any type. Controls 
also completed a detailed questionnaire about smoking 
habits, work, and health history. The category of former 
smokers included NSCLC patients who had quit smoking 
at least one year before diagnosis and controls who had quit 
smoking at least one year before the interview. All 
participants were Caucasian and gave informed consent to 
participate in writing. The study was approved by the 
Medical Ethics Board of the Ataturk Pulmonary Diseases 
and Thoracic Surgery Hospital.
Genomic DNA samples for genetic polymorphism 
analysis were obtained from the blood drawn into coded 
10 mL heparinised tubes and isolated with a DNA 
purification kit according to the manufacturer’s instructions 
(Promega, Fitchburg, WI, USA). Isolated DNA was kept 
at -20 °C until use.
The TP53 (Arg72Pro) polymorphism (rs1042522) was 
identified using the real-time polymerase chain reaction 
(PCR) as described by Talseth et al. (21). The CYP2E1*5B 
(RsaI/PstI, rs3813867/rs2031920) polymorphism was 
identified with the PCR-restriction fragment length 
polymorphism (PCR-RFLP) method described by Hayashi 
et al. (15) and confirmed by real-time PCR as described by 
Choi et al. (22).
Laboratory personnel were not informed about the 
source of DNA samples. For quality control we randomly 
selected 10 % of the samples, and the repeated genotyping 
procedures gave 100 % concordance. All genotyping data 
were independently reviewed by two authors.
Statistical analysis
For the comparison of mean age and pack-years between 
cases and controls we used Student’s t-test. Multivariate 
logistic regression was used to calculate odds ratios (OR) 
between genotypes and NSCLC and 95 % confidence 
intervals adjusted for age, gender, and smoking status. 
Gene-smoking interaction adjusted for age was tested on 
the multiplicative scale by entering product terms in the 
multivariate logistic models. P values below 0.05 were 
considered significant. For statistical analysis we used the 
SPSS 15.0 software package (SPSS Inc., Chicago, IL, 
USA).
RESULTS
Table 1 shows the demographic information for all 
participants. NSCLC patients had significantly higher 
values of pack years smoked than controls (56 and 15 
respectively) (p<0.05).
Table 2 shows the distribution of the TP53 and CYP2E1 
genotypes and adjusted ORs for NSCLC. When calculating 
the ORs, we took wild-type or positive genotypes as 
reference. As we did not detect the homozygous mutant 
genotype (*5B/*5B) (c2/c2) of CYP2E1 in either group, we 
combined heterozygous and homozygous genotypes of 
other polymorphisms for the statistical analysis throughout 
the study and have presented the results accordingly. The 









Male 156 (91) 156 (91)
Mean age 57 52
Age range 34-75 28-78
Female 16 (9) 16 (9)
Mean 55 65
Age range 26-70 32-76
Smoking, n (%)
Current smoker 102 (59) 96 (56)
Former smoker 55 (32) 22 (13)
Non smoker 15 (9) 54 (31)
Pack years, mean* 56 15




*includes current and former smokers (ever smokers)
SCC: squamous cell carcinoma, AC: adenocarcinoma, UNSCLC: 
unspecified non-small cell lung cancer
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combinations with GSTM1, GSTT1, GSTP1 (Ile105Val) 
and GSTP1 (Ala114Val) genotypes (Table 3).
We did not analyse the risk of histological subtypes with 
combined genotypes because of the small number of 
subjects in each subgroup.
As for the multivariate analysis of gene interactions 
with cigarette smoking, we found no significant association 
with the NSCLC risk (data not shown).
DISCUSSION
This is the first study demonstrating the association 
between TP53 (Arg72Pro) polymorphism and the NSCLC 
risk in a Turkish population. Individuals carrying this 
variant had a 2.2 times higher risk than controls. TP53 
polymorphisms have widely been studied in NSCLC, but 
the results are contradictory. Three studies reported a 
significantly increased risk (23-25), one (26) reported an 
insignificant risk increase, and three (9, 17, 27) reported no 
significant association between TP53  codon72 
polymorphism and NSCLC. Along with Liu et al. (23), Yang 
et al. (24), and Loginov et al. (25), we, however, believe to 
be on the right track, since this TP53 variant has lower 
activity in apoptosis and its association with an increased 
NSCLC risk is plausible.
Studies investigating the effect of the CYP2E1*5B 
polymorphism on NSCLC risk also reported inconsistent 
results (17, 28-32).
After the analysis of NSCLC subtypes, we found that 
the variant (Pro) allele carriers of TP53 codon72 were 
significantly associated with the risk of SCC but not AC. 
Tan et al. (18) also reported an association with SCC, but 
Liu et al. (23) reported a significantly increased risk of AC 
TP53 (Arg72Pro) polymorphism was in agreement with the 
Hardy-Weinberg equilibrium in the controls but not in the 
NSCLC patients.
We found a significant association between the TP53 
codon72 heterozygous (Arg/Pro) genotype and the risk of 
NSCLC (OR 2.87; 95 % CI 1.70-4.85; p=0.001). The 
association was not significant between TP53 codon72 
mutant (Pro/Pro) genotype and NSCLC (OR 1.34, 95 % CI 
0.52-3.49; p=0.546), possibly due to the low number of 
Pro/Pro genotype carriers in both the NSCLC (n=13) and 
control group (n=15). When we combined the TP53 
codon72 Arg/Pro and Pro/Pro genotypes, we found a 
significant association between NSCLC risk and the 
genotypes containing variant allele, as shown in Table 2. 
The analysis of NSCLC subtypes showed a significant risk 
of squamous cell carcinoma and unspecified NSCLC in 
patients carrying the variant (Pro) allele of the TP53 
codon72 (OR 3.50; 95 % CI 1.76–6.99; p=0.001 and OR 
3.22, 95 % CI 1.49–6.95; p=0.003, respectively) but not of 
adenocarcinoma (1.34, 95 % CI 0.72-2.51; p=0.360).
Table 3 shows no significant difference between TP53 
and CYP2E1 gene interactions and the risk of NSCLC (top 
results). We then looked further to find if these variant 
genotypes would be associated with increased NSCLC risk 
if combined with the GSTM1, GSTT1, and GSTP1 
polymorphisms from our earlier study (19) and found a 
significant association for TP53 codon72 Arg/Pro and Pro/
Pro in combination with the GSTM1 null genotypes. A 
similar significant association with NSCLC risk was found 
for the combinations of TP53 codon72 Arg/Pro and Pro/
Pro with the GSTT1 null and the GSTP1 (Ala114Val) 
genotypes (Table 3).
In contrast, the combination of TP53 codon72 with the 
GSTP1 (Ile105Val) variant was not significantly associated 
with the NSCLC risk, nor were the CYP2E1 genotype 
Table 2 NSCLC risk association with TP53 and CYP2E1 polymorphisms
Genotype Controls, n (%) NSCLC patients, n (%) OR* (95%CI) p value
TP53
Arg/Arg 88 (51.16) 57 (33.14) 1
Arg/Pro+Pro/Pro 84 (48.84) 115 (66.86) 2.21 (1.39-3.51) 0.001
CYP2E1 
*1A/*1A (c1/c1) 162 (94.19) 165 (95.93) 1
*1A/*5B (c1/c2) 10 (5.81) 7 (4.07) 0.81 (0.28-2.31) 0.695
TP53 Controls, n (%) SCC patients, n (%) OR* (95%CI) p value
Arg/Arg 88 (51.16) 18 (27.69) 1
Arg/Pro+Pro/Pro 84 (48.84) 47 (72.31) 3.50 (1.76-6.99) 0.001
TP53 Controls, n (%) AC patients, n (%) OR* (95%CI) p value
Arg/Arg 88 (51.16) 26 (44.07) 1
Arg/Pro+Pro/Pro 84 (48.84) 33 (55.93) 1.34 (0.72-2.51) 0.360
TP53 Controls, n (%) UNSCLC patients, n (%) OR* (95%CI) p value
Arg/Arg 88 (51.16) 13 (27.08) 1
Arg/Pro+Pro/Pro 84 (48.84) 35 (72.92) 3.22 (1.49-6.95) 0.003
*OR-odds ratio (95 % confidence interval) and p values obtained by multivariate logistic regression adjusted for age, gender, and 
smoking. Wild-type and positive genotypes were taken as reference
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but not of SCC. These inconsistent findings need to be 
clarified in larger future studies.
Our analysis of the potential effect of gene interactions 
on NSCLC risk was motivated by the fact that cancer is a 
complex, multigene process and that individual susceptibility 
to cancer varies. The association between NSCLC risk and 
the TP53 (Arg72Pro) polymorphism in combination with 
genes encoding enzymes involved in tobacco-specific 
carcinogen metabolism has not been well studied so far. In 
our study, the combination of the TP53 codon72 and the 
CYP2E1*5B variants was not significantly associated with 
NSCLC. In Asian populations, the CYP2E1*5B 
polymorphism was found to be associated with lower 
NSCLC risk (32). Although this variant allele was relatively 
rare in our Caucasian participants compared to Asian 
populations, it may have countered the risk increased by 
the TP53 codon72 variant, because their combination was 
not associated with NSCLC. However, we cannot exclude 
the possibility that the observed findings are pure chance.
We have also analysed the interactions between TP53 
and CYP2E1 gene polymorphisms and the GST gene 
(GSTM1, GSTT1 and GSTP1) polymorphisms that we had 
previously determined in the same patients in our 2012 
study (19) to see whether they may affect the NSCLC risk. 
Our results confirm the findings of Klinchid et al. (33), who 
found a significant association between the TP53 codon72 
variant and GSTM1 null combination and NSCLC. The 
highest risk of NSCLC was associated with the TP53 
codon72 variant plus GSTP1 (Ala114Val) variant 
combination (OR=3.38). This combination increases the 
Table 3 NSCLC risk association with TP53, CYP2E1, and GST genotype combinations
Genotype combinations Controls (n) NSCLC patients (n) OR* (95 %CI) p value
TP53, CYP2E1*5B
Arg/Arg, *1A/*1A 82 53 1
Arg/Pro, Pro/Pro, *1A/*5B 4 3 1.16 (0.25-5.39) 0.849
TP53, GSTM1
Arg/Arg, positive 43 29 1
Arg/Pro, Pro/Pro, null 48 72 2.22 (1.23-4.04) 0.009
Arg/Pro, null 40 63 2.35 (1.18-4.71) 0.015
Pro/Pro, null 8 9 1.55 (0.49-4.94) 0.455
TP53, GSTT1
Arg/Arg, positive 72 43 1
Arg/Pro, Pro/Pro, null 18 32 2.98 (1.49-5.94) 0.002
Arg/Pro, null 15 24 2.31 (1.04-5.13) 0.040
Pro/Pro, null 4 8 3.55 (0.92-3.69) 0.065
TP53, GSTP1 (Ile105Val)
Arg/Arg, Ile/Ile 51 36 1
Arg/Pro, Pro/Pro, Ile/Val, Val/Val 36 41 1.61 (0.87-2.99) 0.129
TP53, GSTP1 (Ala114Val)
Arg/Arg, Ala/Ala 76 45 1
Arg/Pro, Pro/Pro, Ala/Val, Val/Val 12 24 3.38 (1.54-7.41) 0.002
CYP2E1*5B, GSTM1
*1A/*1A, positive 76 66 1
*1A/*5B, null 7 1 0.16 (0.20-1.37) 0.095
CYP2E1*5B, GSTT1
*1A/*1A, positive 130 121 1
*1A/*5B, null 2 2 1.07 (0.15-7.75) 0.943
CYP2E1*5B, GSTP1 (Ile105Val) 
*1A/*1A, Ile/Ile 93 105 1
*1A/*5B, Ile/Val, Val/Val 4 2 0.44 (0.79-2.47) 0.353
CYP2E1*5B, GSTP1 (Ala114Val)
*1A/*1A, Ala/Ala 139 130 1
*1A/*5B, Ala/Val, Val/Val 1 1 1.07 (0.07-17.27) 0.962
*OR-odds ratio (95 % confidence interval) and p values obtained by multivariate logistic regression adjusted for age, gender, and 
smoking. Wild-type and positive genotypes were taken as reference
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risk of NSCLC 1.5 times over either variant alone. These 
findings are consistent with the effect of the mutant TP53, 
which impairs the apoptosis of transforming tumour cells, 
while lower GST variant activity insufficiently detoxifies 
carcinogenic chemicals.
What may limit the interpretation of our findings is a 
relatively small sample size, yet they clearly point that the 
TP53 (Arg72Pro) polymorphism alone and in combination 
with GSTM1, GSTT1, or GSTP1 (Ala114Val) may increase 
the risk of NSCLC, the last combination in particular. 
Further studies with larger samples are needed to verify 
these findings.
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Povezanost polimorfizama gena TP53 i CYP2E1*5B s nemikrocelularnim karcinomom pluća
Nemikrocelularni karcinom pluća (engl. non-small cell lung cancer – NSCLC) najčešći je oblik karcinoma pluća. 
Polimorfizimi gena za supresiju tumora i gena koji kodiraju enzime za razgradnju ksenobiotika mijenjaju aktivnost tih 
gena te značajno utječu na individualnu sklonost nastanku NSCLC-a. Budući da u literaturi nema dovoljno saznanja o 
njihovu utjecaju na nastanak bolesti, cilj je ovoga ispitivanja bio utvrditi povezanost polimorfizama tumorskoga 
supresorskoga gena TP53 (Arg72Pro), odnosno gena CYP2E1*5B za metabolizam ksenobiotika, s rizikom od NSCLC-a. 
Ispitivanje je obuhvatilo 172 bolesnika s NSCLC-om i 172 kontrolna ispitanika (po 156 muškaraca i 16 žena u svakoj 
skupini). Genski su polimorfizmi utvrđeni polimeraznom lančanom reakcijom u stvarnom vremenu (engl. real-time 
polymerase chain reaction – RT-PCR) te kombinacijom PCR-a s metodom cijepanja DNA restrikcijskim enzimima (engl. 
restriction fragment length polymorphism – PCR-RFLP). Multivarijantna analiza upozorava na značajnu povezanost 
kombinacije TP53 kodon72 Arg/Pro i Pro/Pro genotipova s NSCLC-om (OR 2,21; 95 % CI 1,39-3,51; p=0,001). Također 
je analizirana povezanost kombinacija ovih genskih varijanta s polimorfizmima gena glutation S-tranferaze GSTM1, 
GSTT1, GSTP1 ekson 5 (Ile105Val) i GSTP1 ekson 6 (Ala114Val) s rizikom od NSCLC-a te utvrđeno značajno povećanje 
rizika kod sljedećih kombinacija: TP53 kodon72 s GSTM1 nula (OR 2,22; 95 % CI 1,23-4,04; p=0,009), GSTT1 nula 
(OR 2,98; 95 % CI 1,49-5,94; p=0,002) i GSTP1 (Ala114Val) (OR 3,38; 95 % CI 1,54-7,41; p=0,002). Da bi se potvrdili 
ovi preliminarni rezultati, potrebna su istraživanja na većim uzorcima.
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